Galderma received FDA approval for Restylane Contour for the correction of temple hollowing, a narrowly defined indication that reflects the industry's shift toward anatomically specific filler claims. Temple volume loss is a recognized sign of aging but has historically been treated off-label with standard volumizers; this approval gives Galderma a named indication and a marketing advantage in that zone.
Injectables
Galderma Wins FDA Clearance for Restylane Contour in Temple Hollowing — Narrower Indication, Broader Competitive Pressure
Galderma's latest Restylane indication targets temple volume loss; the approval underscores the race to own specific anatomical zones.
Temple hollowing is now an FDA-indicated use for Restylane Contour.
The approval matters less for clinical efficacy (practitioners already treat temples) and more for label authority and payer recognition. For practices, it's a reminder that Galderma is systematically building out the Restylane portfolio — Contour now covers temples, while Restylane Lyft and Volbella hold their own indications. This fragmentation of the filler market by anatomy and mechanism (Contour's rheology differs from Lyft) requires practices to stock multiple SKUs and educate staff on the clinical rationale for each. Allergan's Skinvive approval in the same window signals an arms race in indication expansion.
Source: original report ↗
Frequently asked questions
Can you use Restylane Contour for temple hollowing?
Yes. Galderma received FDA approval for Restylane Contour specifically for correction of temple hollowing, a narrowly defined indication that gives practices label authority to treat temple volume loss. This approval marks the first named indication for this anatomical zone, though practitioners have historically treated temples off-label with standard volumizers.
What's the difference between Restylane Contour, Lyft, and Volbella?
Each Restylane product targets different anatomical zones and has distinct rheology. Contour is now indicated for temple hollowing, Lyft is designed for deeper volumization, and Volbella targets lips and perioral lines. The differences in gel structure and particle size mean practices need to stock multiple SKUs and train staff on the clinical rationale for each.
Why does FDA approval for a specific body part matter if doctors already treat it off-label?
Label approval provides marketing authority, payer recognition, and competitive positioning—not necessarily new clinical capability. For Galderma, the temple hollowing indication lets them claim a named zone and differentiate Restylane Contour in marketing, while practices gain the ability to bill and communicate the treatment as an approved use rather than off-label.
Is there competition for temple filler indications?
Yes. Allergan's Skinvive approval in the same window signals an industry-wide arms race in indication expansion. Manufacturers are systematically building out anatomically specific claims to own particular facial zones and gain competitive advantages in marketing and payer negotiations.
What does temple hollowing approval mean for medspa inventory?
It reinforces the need to stock multiple filler products with different indications and rheologies. Practices must now educate staff on when to recommend Restylane Contour for temples versus Lyft or Volbella for other zones, increasing complexity in product selection and staff training.
Free weekly brief
Get the free weekly brief.
The week's most important moves in medical aesthetics — distilled to a two-minute read, free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief every morning. The owners who read it never get blindsided.
Get the edge · $20/moJoin the owners who run ahead of the industry. Cancel anytime, one click.